VA
ACLX

Vident Advisory’s Arcellx ACLX Stock Holding History

Vident Advisory’s Portfolio ACLX Stock Details ACLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$264K Buy
+2,298
New +$203K ﹤0.01% 1569

Other funds holding ACLX

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Vident Advisory's ACLX Position: Q1 2026 in Review

Vident Advisory opened a new position in Arcellx (ACLX) in Q1 2026: 2,298 shares worth $264K. The stake represents ﹤0.01% of the portfolio and ranks #1569 among its holdings.

239 funds tracked by Wall St. Rank hold ACLX as of Q1 2026.

  • Vident Advisory held 2,298 shares of Arcellx worth $264K as of Q1 2026.
  • Arcellx was a new Vident Advisory position in Q1 2026.
  • Arcellx made up ﹤0.01% of Vident Advisory's portfolio in Q1 2026, its #1569 holding.
  • 239 funds tracked by Wall St. Rank held Arcellx as of Q1 2026.

Based on Vident Advisory's 13F filing for Q1 2026, filed 15 May 2026.